Clinical Trials Logo

Craniopharyngioma clinical trials

View clinical trials related to Craniopharyngioma.

Filter by:

NCT ID: NCT00363272 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Start date: June 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

NCT ID: NCT00306683 Completed - Craniopharyngiomas Clinical Trials

Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions

Start date: April 2006
Phase: Phase 3
Study type: Interventional

In children treated for intracranial lesions, the 2 factors of the obesity are : the location of the lesion (hypothalamic-pituitary region) and craniopharyngiomas

NCT ID: NCT00258453 Completed - Clinical trials for Brain and Central Nervous System Tumors

Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma

Start date: May 2001
Phase: N/A
Study type: Interventional

RATIONALE: Collecting information on how craniopharyngioma is diagnosed and treated may help doctors predict a patient's response to treatment and help plan the best treatment. It may also help identify the intermediate- and long-term effects of treatment. PURPOSE: This clinical trial is collecting information on diagnosis, treatment, and quality of life of young patients who are undergoing surgery for craniopharyngioma.

NCT ID: NCT00100880 Completed - Clinical trials for Recurrent Childhood Ependymoma

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.

NCT ID: NCT00063973 Completed - Clinical trials for Recurrent Childhood Ependymoma

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.

NCT ID: NCT00053963 Completed - Clinical trials for Refractory Chronic Lymphocytic Leukemia

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Start date: September 2002
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00052780 Completed - Clinical trials for Recurrent Childhood Ependymoma

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Start date: October 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. O6-benzylguanine may increase the effectiveness of temozolomide by making tumor cells more sensitive to the drug.

NCT ID: NCT00019578 Completed - Brain Metastases Clinical Trials

Stereotactic Radiosurgery in Treating Patients With Brain Tumors

Start date: November 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.

NCT ID: NCT00004078 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Irinotecan in Treating Children With Refractory Solid Tumors

Start date: October 1999
Phase: Phase 2
Study type: Interventional

This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.